Decatecholaminisation of Septic Shock With Dexmedetomidine and In-hospital Mortality

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to determine whether the infusion of DEX in septic shock can reduce in-hospital mortality, norepinephrine infusion, need and duration for mechanical ventilation, and acute kidney injury without significant adverse events.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Adult (≥ 18 years) patients of either sex who develop septic shock with heart rate (HR) > 90 beats per minute (bpm).

We choose the definition of septic shock as the start of norepinephrine (NE) infusion to maintain the mean arterial blood pressure (MAP) of ≥ 65 mmHg in a case of sepsis (≥ 2 SIRS criteria plus suspicion or confirmation of infection).

Exclusion Criteria:

• Patient refusal or inability to obtain consent

• Failure of hemodynamic stabilization or hemoglobin < 7 gm/dl at time of inclusion

• Severe cardiac dysfunction (Ejection Fraction (EF) < 30%)

• History of heart block or patient on pacemaker

• Chronic liver Disease (Child-Pugh classification C)

• Severe valvular heart disease

• Pregnancy